57 results about "Renal disorder" patented technology

The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and / or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

Methods for diagnosing renal disorders by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided.

The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and / or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIRAs) with one or more OP / BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIRAs with those morphogens.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.

The present invention provides a system comprising an array of chemically sensitive sensors based on coated single walled carbon nanotubes, for measuring volatile organic compounds indicative of renal failure. Methods of breath analysis for diagnosing chronic, acute and end-stage renal failure are disclosed.

The disclosure provides methods for treating, preventing, and reducing risk of occurrence of renal insufficiency in mammals. The disclosed methods include administering to a subject susceptible to, or afflicted with, renal disorder therapeutically effective amounts of a TGF-β antagonist and a renin-angiotensin-aldosterone system (RAAS) antagonist so as to maintain desirable levels of renal function. The populations treated by the methods of the invention include but are not limited to patients suffering or at risk for the development of renal insufficiency, such as those afflicted with type I or type II diabetes, hypertension, (auto)immune disease, systemic fibrosis, etc.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and / or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B orα2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and / or monitoring of treatment regimens.

Disclosed herein are methods, compounds and compositions for preventing or treating a renal disorder or chronic kidney diseases, including nephropathies such as diabetic nephropathy. The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for the prevention and / or treatment of for preventing or treating a renal disorder complication. The invention further relates to methods, compounds and compositions for the prevention and / or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in diabetic patients.

Methods and devices for diagnosing, monitoring, or determining a renal disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining a renal disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

The present invention relates generally to a method for the treatment of renal failure or renal hypertension and, more particularly, for improving the recovery from acute renal failure or renal hypertension by treatment with activators of soluble guanylate cyclase or stimulators of guanylate cyclase.

Disclosed herein are methods, compounds and compositions for preventing or treating a renal disorder or chronic kidney diseases, including nephropathies such as diabetic nephropathy. The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for the prevention and / or treatment of for preventing or treating a renal disorder complication. The invention further relates to methods, compounds and compositions for the prevention and / or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in diabetic patients.

The present invention relates to reduction of side effects of diclofenac or a salt thereof An agent for reducing side effects of diclofenac or a salt thereof which comprises ornoprostil. It is expected that a combination agent of diclofenac or a non-toxic salt thereof and ornoprostil is comparable to even superior to marketed diclofenac tablets or Arthrotec tables in effects and fast-acting property while showing little side effects (particularly digestive disorders, gastric ulcer, diarrhea / vomiting and renal disorder) and exerting excellent antipyretic, analgesic and antiinlfammatory effects. Also, by formulating the combination agent into a preparation of separation type pharmaceutical preparation, the stability of ornoprostil can be improved.

The disclosure relates to treatment of immunological disorders, including but not limited to renal disorders associated with immunoglobulin deposits. The disclosure further relates to the lymphotoxin pathway. Compositions comprising lymphotoxin pathway inhibitors are described.

A method preserving renal medullary blood flow in a renal disorder in a human or non-human animal is disclosed. The method involves administering 20-HETE or a 20-HETE analog to the human or non-human animal in an amount sufficient to attenuate a fall in renal medullary blood flow following a renal disorder. In addition, a method for preventing and treating ischemic acute renal failure is disclosed. The method involves administering 20-HETE or a 20-HETE agonist to the human or non-human animal in an amount sufficient to prevent or treat ischemic acute renal failure.

The present invention relates to salts of 3-pentylphenylacetic acid and their pharmaceutical uses. Particular aspects of the invention relate to the use of those salts in the prevention and / or treatment of various diseases and conditions in subjects, including the prevention and treatment of (i) blood disorders, (ii) renal disorders and renal disorder complications; (iii) inflammatory-related diseases; and / or (iv) oxidative stress related disorders.

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

The present invention relates to a method of suppressing malignant conditions, including cancer with complications such like liver disorder, renal disorder and platelet disorder in bleeding, by administering a composition of an extract of Canavalia ensiformis. Also, the invention is nontoxic to the individual and for improving functions of kidney as well as of liver, especially when involved in cancer.

The present invention provides methods of treating proteinuria, and treating renal disorders associated with proteinuria, the methods generally involving administering to an individual having such a disorder an effective amount of retinoic acid receptor agonist or a retinoid X receptor agonist.

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

To provide a novel biomarker that is useful for prediction of early onset of acute kidney injury, estimation of prognosis associated with a renal function, and differentiation of acute kidney injury. Furthermore, to provide use of the novel biomarker. Midkine is used as a biomarker. The determination of a possibility of the onset of acute kidney injury, estimation of prognosis associated with a renal function or differentiation of an acute kidney injury are carried out based on the detection result of the urinary midkine.

The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.

Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R═C(0); —OC(O)— or —CH(OH)—; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and / or renal disorders complications, or (iv) fibrosis-related organ dysfunction.

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent renal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are methods of assessing the effect of an agent on renal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are models of renal disorder. In one embodiment, disclosed are models of renal fibrosis, comprising a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are methods of making the model of renal disorder. In one embodiment disclosed are methods of making the model of renal fibrosis comprising contacting a three-dimensional, engineered, bioprinted, biological renal tubule model with an agent that is capable of inducing interstitial fibrotic tissue formation.

The present invention relates to parstatin peptides, compositions comprising parstatin peptides and their use in the treatment of various disorders, including angiogenesis-related diseases, ocular neovascularization and related disease states, ischemia-reperfusion injury and myocardial-related disease states, and renal disorders.

The invention provides a traditional Chinese medicine composition for treatment of chronic renal diseases and its preparation method and use. The traditional Chinese medicine composition is prepared from the raw material medicines of rheum officinale, astragalus and safflower with a weight ratio of 3-45:9-85:3-65 by a certain extraction and purification process into an injection, a freeze-dried powder injection or other oral preparations. Animal experiments confirm that, the traditional Chinese medicine composition can obviously improve the hemodynamic indexes of rats subjected to chronic glomerulonephritis, reduces serum IL-6, IL-8, and TNF (tumor necrosis factor)-alpha levels, significantly reduces serum creatinine and urea nitrogen and other indexes of rats subjected to hypertensive nephropathy, significantly reduces serum urea nitrogen and serum creatinine contents of rats subjected to chronic renal failure, increases serum albumin content, and also can improve each hemodynamic index of rats subjected to the chronic renal failure; and pathological results show that the traditional Chinese medicine composition can improve and inhibit injures on kidney caused by the chronic renal diseases and chronic renal failure.